^
    Back
    Association details:
    Biomarker:YAP1 overexpression
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Gland Surg
    Title:

    The prognostic effect of HER2 heterogeneity and YAP1 expression in HER2 positive breast cancer patients: a retrospective study

    Published date:
    02/01/2022
    Excerpt:
    Over-expression and nuclear localization of YAP1 were significant in HER2-ITH patients....HER2-NITH patients and YAP1-insufficient patients benefited from a combination of Trastuzumab and Pertuzumab/Lapatinib, while Capecitabine significantly decreased the relapse risk of ITH patients and YAP1-sufficient patients....YAP1 overexpression contributed to a poor prognostic outcome, especially when HER2 signal intensity was insufficient.
    DOI:
    10.21037/gs-22-52